Global CD22 Targeted Therapies Market, Approved Drug Sales, Technology Platforms & Clinical Trials Insight 2026
This report provides a detailed and comprehensive review of CD22 targeting therapies, offering key insights into the therapeutic potential of this emerging class of treatments across a broadening range of indications. While the development of CD22-targeting therapies started off with acute lymphoblastic leukemia and B-cell lymphomas, studies are increasingly considering their value in other indications like autoimmune disorders, neurodegenerative diseases, and other immune-mediated diseases. The data gathered, analyzed, and interpreted for this report contribute to a balanced view of CD22 as a multifunctional therapeutic target. Mechanisms of action are discussed, along with clinical development and available therapies, while the rationale for the use of CD22 modulation is extended across disease categories. The report summarizes, in an accessible format, all available information through a wide research approach that will be of importance to drug developers, clinical investigators, market analysts, and policy decision makers.
The report is targeted at pharmaceutical developers, clinicians, investors, and regulatory strategists seeking information on the current and future landscape of CD22-targeting agents. It aims to provide a current and realistic market view with regard to the size, direction, and trends of this therapeutic area. To achieve this, primary and secondary data sources from a wide range of credible outlets were used to develop an integrated and reliable assessment. The structure of the report enables deep exploration of key data points, including candidate molecules, clinical outcomes, evolving disease applications, and long-term development patterns.
A database compiled for the report focuses on the biological function of CD22 in immune signaling and its relevance to disease processes. This section outlines why the expression of CD22 on B-cells, which thereby modulates immune activation and tolerance, makes it an attractive therapeutic target. It describes how a variety of therapeutic platforms, such as antibody-drug conjugates and immunotoxins directed against CD22, achieve selective delivery of cytotoxic or modulatory payloads. An analysis of the underlying biology that informs established and emerging therapeutic strategies is laid out in a clear format for stakeholders looking for the scientific rationale behind CD22 modulation.
The secondary database in the report provides comprehensive details on marketed and investigational therapies that target CD22, including specific clinical and regulatory events across the United States, Europe, and the developing markets. Emphasis is provided for two agents that have gained FDA approval to date: the currently marketed Besponsa (inotuzumab ozogamicin), analyzed regarding its efficacy, safety, pricing, dosing, and sales; and the immunotoxin Lumoxiti (moxetumomab pasudotox), which received FDA approval and then was subsequently taken off the market, where factors regarding its product lifecycle will be examined.
It involves a comprehensive search of the clinical trial landscape for therapies targeting CD22, sourced from publicly available trial registries, peer-reviewed journals, company disclosures, and data releases by major pharmaceutical sponsors. The trials were studied in various patient populations and disease settings to understand both established and exploratory uses. The review covers aspects related to trial design, participant characteristics, dosing regimens, treatment combinations, and outcomes. Particular attention is given to studies in relapsed or refractory conditions and toward emerging indications beyond oncology, which are immune dysregulation and neurological disorders. Possible segmentations of patient groups depending on biomarkers, disease subtype, or immune characteristics will also be analyzed.
Combination-therapy strategies are discussed in detail, including studies pairing CD22-targeting agents with immunomodulators, targeted small molecules, or traditional therapeutics. Early-stage programs assessing synergy with next-generation immune technologies are also discussed, illustrating how CD22-targeted agents may be incorporated into evolving multimodal treatment strategies.
The report goes on to explore the technological platforms that are developing for CD22-targeting therapies. Gene-editing technologies such as CRISPR/Cas9 and TALEN are discussed as being applied toward developing CD22-targeted engineered immune cell therapies, including allogeneic CAR-T constructs such as UCART22. These technologies allow for precise modification of cellular products to enhance potency, persistence, and safety. Furthermore, nanobody-based modalities are discussed, which utilize small, highly stable antibody fragments that demonstrate tight binding to CD22, thus enabling alternative therapeutic formats and delivery methods that might extend their applicability across indications.
Key companies contributing to the innovation in CD22-targeted therapeutics are profiled, including major pharmaceutical developers and emerging biotechnology firms. Their R&D pipelines, strategic partnerships, investment patterns, and competitive positioning are analyzed to provide a comprehensive view of activity within the field. Additionally, the report assesses commercial dynamics including pricing strategies, revenue trends, global distribution considerations, and the regulatory pathways that shape market access across the US, EU, and Asia.
It discusses long-term prospects for CD22-targeting therapies, with a focus on new clinical opportunities, scientific developments, and possible applications beyond established immune-related and hematological diseases. Early investigations into neurological and autoimmune indications are considered, along with the potential for CD22-modulating approaches to support future treatment paradigms. Estimates of market growth and investment opportunities are provided in order to contextualize future development.
Data included in the report are cross-checked against peer-reviewed publications, clinical trial databases, corporate financial reports, and expert interviews. Clinical datasets were examined for accuracy, consistency, and relevance to ensure that insights reflect the most current and reliable evidence. This rigorous methodology will underpin a comprehensive, data-driven evaluation of therapies targeting CD22, forming the basis for an informed decision-making process in research, development, investment, and policy planning.
The report is targeted at pharmaceutical developers, clinicians, investors, and regulatory strategists seeking information on the current and future landscape of CD22-targeting agents. It aims to provide a current and realistic market view with regard to the size, direction, and trends of this therapeutic area. To achieve this, primary and secondary data sources from a wide range of credible outlets were used to develop an integrated and reliable assessment. The structure of the report enables deep exploration of key data points, including candidate molecules, clinical outcomes, evolving disease applications, and long-term development patterns.
A database compiled for the report focuses on the biological function of CD22 in immune signaling and its relevance to disease processes. This section outlines why the expression of CD22 on B-cells, which thereby modulates immune activation and tolerance, makes it an attractive therapeutic target. It describes how a variety of therapeutic platforms, such as antibody-drug conjugates and immunotoxins directed against CD22, achieve selective delivery of cytotoxic or modulatory payloads. An analysis of the underlying biology that informs established and emerging therapeutic strategies is laid out in a clear format for stakeholders looking for the scientific rationale behind CD22 modulation.
The secondary database in the report provides comprehensive details on marketed and investigational therapies that target CD22, including specific clinical and regulatory events across the United States, Europe, and the developing markets. Emphasis is provided for two agents that have gained FDA approval to date: the currently marketed Besponsa (inotuzumab ozogamicin), analyzed regarding its efficacy, safety, pricing, dosing, and sales; and the immunotoxin Lumoxiti (moxetumomab pasudotox), which received FDA approval and then was subsequently taken off the market, where factors regarding its product lifecycle will be examined.
It involves a comprehensive search of the clinical trial landscape for therapies targeting CD22, sourced from publicly available trial registries, peer-reviewed journals, company disclosures, and data releases by major pharmaceutical sponsors. The trials were studied in various patient populations and disease settings to understand both established and exploratory uses. The review covers aspects related to trial design, participant characteristics, dosing regimens, treatment combinations, and outcomes. Particular attention is given to studies in relapsed or refractory conditions and toward emerging indications beyond oncology, which are immune dysregulation and neurological disorders. Possible segmentations of patient groups depending on biomarkers, disease subtype, or immune characteristics will also be analyzed.
Combination-therapy strategies are discussed in detail, including studies pairing CD22-targeting agents with immunomodulators, targeted small molecules, or traditional therapeutics. Early-stage programs assessing synergy with next-generation immune technologies are also discussed, illustrating how CD22-targeted agents may be incorporated into evolving multimodal treatment strategies.
The report goes on to explore the technological platforms that are developing for CD22-targeting therapies. Gene-editing technologies such as CRISPR/Cas9 and TALEN are discussed as being applied toward developing CD22-targeted engineered immune cell therapies, including allogeneic CAR-T constructs such as UCART22. These technologies allow for precise modification of cellular products to enhance potency, persistence, and safety. Furthermore, nanobody-based modalities are discussed, which utilize small, highly stable antibody fragments that demonstrate tight binding to CD22, thus enabling alternative therapeutic formats and delivery methods that might extend their applicability across indications.
Key companies contributing to the innovation in CD22-targeted therapeutics are profiled, including major pharmaceutical developers and emerging biotechnology firms. Their R&D pipelines, strategic partnerships, investment patterns, and competitive positioning are analyzed to provide a comprehensive view of activity within the field. Additionally, the report assesses commercial dynamics including pricing strategies, revenue trends, global distribution considerations, and the regulatory pathways that shape market access across the US, EU, and Asia.
It discusses long-term prospects for CD22-targeting therapies, with a focus on new clinical opportunities, scientific developments, and possible applications beyond established immune-related and hematological diseases. Early investigations into neurological and autoimmune indications are considered, along with the potential for CD22-modulating approaches to support future treatment paradigms. Estimates of market growth and investment opportunities are provided in order to contextualize future development.
Data included in the report are cross-checked against peer-reviewed publications, clinical trial databases, corporate financial reports, and expert interviews. Clinical datasets were examined for accuracy, consistency, and relevance to ensure that insights reflect the most current and reliable evidence. This rigorous methodology will underpin a comprehensive, data-driven evaluation of therapies targeting CD22, forming the basis for an informed decision-making process in research, development, investment, and policy planning.
1. RESEARCH METHODOLOGY
2. INTRODUCTION TO CD22
2.1 Overview Of CD22 Targeted Therapies
2.2 Importance Of CD22 In Immunology
3. BIOLOGY OF CD22
3.1 Structure & Function of CD22
3.2 Role In B-cell Development & Function
3.3 Mechanisms Of Action In Immune Response
4. CD22 TARGETED APPROACHES
4.1 Cell Therapies
4.2 Antibody Therapies
4.3 Radioimmunoconjugates
4.4 Nucleic Acids
5. GLOBAL CD22 TARGETED THERAPIES MARKET OUTLOOK
5.1 Current Market Scenario
5.2 Future Market Opportunities
6. BESPONSA ? DOSAGE, PRICE & SALES INSIGHT
6.1 Overview & Availability Insight
6.2 Pricing & Dosage Insight
6.3 Sales Insight
7. CD22 TARGETED THERAPIES REGIONAL MARKET ANALYSIS
7.1 US
7.2 Europe
8. CD22 TARGETED THERAPIES DEVELOPMENT & CLINICAL TRENDS BY INDICATION
8.1 Cancer
8.2 Neurodegenerative Diseases
8.3 Autoimmune & Inflammatory Diseases
8.4 Infectious Diseases
9. GLOBAL CD22 TARGETED THERAPY CLINICAL TRIALS OVERVIEW
9.1 By Country
9.2 By Indication
9.3 By Organization
9.4 By Phase
10. GLOBAL CD22 TARGETED THERAPY CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
10.1 Research
10.2 Preclinical
10.3 Phase I
10.4 Phase I/II
10.5 Preregistration
11. MARKETED CD22 TARGETED THERAPIES CLINICAL INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
12. GLOBAL CD22 TARGETED THERAPIES MARKET DYNAMICS
12.1 Drivers & Opportunities
12.2 Challenges & Solutions
13. CD22 TARGETED THERAPIES DEVELOPMENT PLATFORMS BY COMPANY
14. COMPETITIVE LANDSCAPE
14.1 ADC Therapeutics
14.2 AstraZeneca
14.3 Autolus Therapeutics
14.4 Cellectis
14.5 Century Therapeutics
14.6 Enterome
14.7 Essen BioTech
14.8 Kecellitics Biotech
14.9 ME Therapeutics
14.10 Miltenyi Biomedicine
14.11 Nanjing IASO Biotechnology
14.12 NanoCell Therapeutics
14.13 Onechain Immunotherapeutics
14.14 Pfizer
14.15 Regeneron
14.16 Shanghai Yake Biotechnology
14.17 SinoMab Bioscience
14.18 TuHURA Biosciences
14.19 Umoja Biopharma
2. INTRODUCTION TO CD22
2.1 Overview Of CD22 Targeted Therapies
2.2 Importance Of CD22 In Immunology
3. BIOLOGY OF CD22
3.1 Structure & Function of CD22
3.2 Role In B-cell Development & Function
3.3 Mechanisms Of Action In Immune Response
4. CD22 TARGETED APPROACHES
4.1 Cell Therapies
4.2 Antibody Therapies
4.3 Radioimmunoconjugates
4.4 Nucleic Acids
5. GLOBAL CD22 TARGETED THERAPIES MARKET OUTLOOK
5.1 Current Market Scenario
5.2 Future Market Opportunities
6. BESPONSA ? DOSAGE, PRICE & SALES INSIGHT
6.1 Overview & Availability Insight
6.2 Pricing & Dosage Insight
6.3 Sales Insight
7. CD22 TARGETED THERAPIES REGIONAL MARKET ANALYSIS
7.1 US
7.2 Europe
8. CD22 TARGETED THERAPIES DEVELOPMENT & CLINICAL TRENDS BY INDICATION
8.1 Cancer
8.2 Neurodegenerative Diseases
8.3 Autoimmune & Inflammatory Diseases
8.4 Infectious Diseases
9. GLOBAL CD22 TARGETED THERAPY CLINICAL TRIALS OVERVIEW
9.1 By Country
9.2 By Indication
9.3 By Organization
9.4 By Phase
10. GLOBAL CD22 TARGETED THERAPY CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
10.1 Research
10.2 Preclinical
10.3 Phase I
10.4 Phase I/II
10.5 Preregistration
11. MARKETED CD22 TARGETED THERAPIES CLINICAL INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
12. GLOBAL CD22 TARGETED THERAPIES MARKET DYNAMICS
12.1 Drivers & Opportunities
12.2 Challenges & Solutions
13. CD22 TARGETED THERAPIES DEVELOPMENT PLATFORMS BY COMPANY
14. COMPETITIVE LANDSCAPE
14.1 ADC Therapeutics
14.2 AstraZeneca
14.3 Autolus Therapeutics
14.4 Cellectis
14.5 Century Therapeutics
14.6 Enterome
14.7 Essen BioTech
14.8 Kecellitics Biotech
14.9 ME Therapeutics
14.10 Miltenyi Biomedicine
14.11 Nanjing IASO Biotechnology
14.12 NanoCell Therapeutics
14.13 Onechain Immunotherapeutics
14.14 Pfizer
14.15 Regeneron
14.16 Shanghai Yake Biotechnology
14.17 SinoMab Bioscience
14.18 TuHURA Biosciences
14.19 Umoja Biopharma
LIST OF TABLES
Table 3-1: CD22 Functions Across B-Cell Stages
Table 4-1: CD22 Directed Antibody Based Therapies
Table 3-1: CD22 Functions Across B-Cell Stages
Table 4-1: CD22 Directed Antibody Based Therapies
LIST OF FIGURES
Figure 2-1: CD22 As A Therapeutic Target
Figure 2-2: Evolution Of CD22 Targeted Therapy
Figure 2-3: CD22 In Immune Regulation
Figure 2-4: CD22 In The B-Cell Signaling Network
Figure 2-5: How CD22 Dampens BCR Signaling
Figure 3-1: Domain Architecture Of CD22
Figure 3-2: CD22 Mediated Inhibition Of BCR Signaling
Figure 3-3: Dual Signaling Roles Of CD22
Figure 3-4: CD22 Oligomerization & B-Cell Activation Threshold
Figure 3-5: CD22 Adhesion & Immune Synapse Positioning
Figure 3-6: CD22 In Calcium Regulation
Figure 3-7: CD22?s Multi-Layered Control Of Immune Responses
Figure 4-1: CD22 Targeted CAR-T Cell Therapy - Mechanism
Figure 4-2: Targeting CD22 After CD19 Antigen Escape
Figure 4-3: Multi-Antigen CAR Concept Featuring CD22
Figure 4-4: CD22 Targeted Antibody Based Therapies
Figure 4-5: Besponsa - Mechanism Of Action
Figure 4-6: Lumoxiti - Mechanism Of Action
Figure 4-7: CD22-Targeted Radioimmunoconjugates ? Mechanism Of Action
Figure 4-8: CD22 Radioimmunoconjugates - Advantages
Figure 4-9: CD22 Nucleic Acid Targeting Approaches
Figure 4-10: Targeting CD22 With RNA-Based Therapeutics
Figure 5-1: CLIC-02 Phase 1 (NCT06208735) Study ? Initiation & Completion Year
Figure 5-2: Global CD22 Targeted Therapies Market ? Future Opportunities
Figure 6-1: Besponsa - Approval Year By Region
Figure 6-2: Besponsa ? Cost Of Supply By Region, November?2025
Figure 6-3: Besponsa - Global Annual Sales (US$ Million), 2020-2023
Figure 6-4: Besponsa ? Global Sales by Region (US$ Million), 2023
Figure 6-5: Besponsa - Global Quarterly Sales (US$ Million), Q1-Q4?2023
Figure 8-1: SIDNEY Phase 1/2 (NCT04669171) Study ? Initiation & Completion Year
Figure 8-2: BZE2204-A-01 Phase 1 (NCT06446128) Study ? Initiation & Completion Year
Figure 8-3: BZE2204-C-01 Phase 1 (NCT07174843) Study ? Initiation & Completion Year
Figure 9-1: Global ? Number Of CD22 Targeted Therapy Clinical Trials By Country, 2026
Figure 9-2: Global ? Number Of CD22 Targeted Therapy Clinical Trials By Indication, 2026
Figure 9-3: Global ? Number Of CD22 Targeted Therapy Clinical Trials By Organization, 2026
Figure 9-4: Global ? Number Of CD22 Targeted Therapy Clinical Trials By Phase, 2026
Figure 12-1: Global CD22 Targeted Therapies Market ? Drivers & Opportunities
Figure 12-2: Global CD22 Targeted Therapies Market ? Challenges & Solutions
Figure 13-1: TRAAC - Tallac Therapeutics
Figure 13-2: VivoVec Platform - Unique Features
Figure 13-3: OncoMimics Platoform
Figure 13-4: Cellectis - TALEN Technology
Figure 2-1: CD22 As A Therapeutic Target
Figure 2-2: Evolution Of CD22 Targeted Therapy
Figure 2-3: CD22 In Immune Regulation
Figure 2-4: CD22 In The B-Cell Signaling Network
Figure 2-5: How CD22 Dampens BCR Signaling
Figure 3-1: Domain Architecture Of CD22
Figure 3-2: CD22 Mediated Inhibition Of BCR Signaling
Figure 3-3: Dual Signaling Roles Of CD22
Figure 3-4: CD22 Oligomerization & B-Cell Activation Threshold
Figure 3-5: CD22 Adhesion & Immune Synapse Positioning
Figure 3-6: CD22 In Calcium Regulation
Figure 3-7: CD22?s Multi-Layered Control Of Immune Responses
Figure 4-1: CD22 Targeted CAR-T Cell Therapy - Mechanism
Figure 4-2: Targeting CD22 After CD19 Antigen Escape
Figure 4-3: Multi-Antigen CAR Concept Featuring CD22
Figure 4-4: CD22 Targeted Antibody Based Therapies
Figure 4-5: Besponsa - Mechanism Of Action
Figure 4-6: Lumoxiti - Mechanism Of Action
Figure 4-7: CD22-Targeted Radioimmunoconjugates ? Mechanism Of Action
Figure 4-8: CD22 Radioimmunoconjugates - Advantages
Figure 4-9: CD22 Nucleic Acid Targeting Approaches
Figure 4-10: Targeting CD22 With RNA-Based Therapeutics
Figure 5-1: CLIC-02 Phase 1 (NCT06208735) Study ? Initiation & Completion Year
Figure 5-2: Global CD22 Targeted Therapies Market ? Future Opportunities
Figure 6-1: Besponsa - Approval Year By Region
Figure 6-2: Besponsa ? Cost Of Supply By Region, November?2025
Figure 6-3: Besponsa - Global Annual Sales (US$ Million), 2020-2023
Figure 6-4: Besponsa ? Global Sales by Region (US$ Million), 2023
Figure 6-5: Besponsa - Global Quarterly Sales (US$ Million), Q1-Q4?2023
Figure 8-1: SIDNEY Phase 1/2 (NCT04669171) Study ? Initiation & Completion Year
Figure 8-2: BZE2204-A-01 Phase 1 (NCT06446128) Study ? Initiation & Completion Year
Figure 8-3: BZE2204-C-01 Phase 1 (NCT07174843) Study ? Initiation & Completion Year
Figure 9-1: Global ? Number Of CD22 Targeted Therapy Clinical Trials By Country, 2026
Figure 9-2: Global ? Number Of CD22 Targeted Therapy Clinical Trials By Indication, 2026
Figure 9-3: Global ? Number Of CD22 Targeted Therapy Clinical Trials By Organization, 2026
Figure 9-4: Global ? Number Of CD22 Targeted Therapy Clinical Trials By Phase, 2026
Figure 12-1: Global CD22 Targeted Therapies Market ? Drivers & Opportunities
Figure 12-2: Global CD22 Targeted Therapies Market ? Challenges & Solutions
Figure 13-1: TRAAC - Tallac Therapeutics
Figure 13-2: VivoVec Platform - Unique Features
Figure 13-3: OncoMimics Platoform
Figure 13-4: Cellectis - TALEN Technology
